Is Avidity Biosciences, Inc. (RNA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.6% / 30% | 117.4% / 30% | 0.0% / 30% | 0.06% / 5% | ✗ NOT HALAL |
| DJIM | 1.6% / 33% | 117.4% / 33% | 0.0% / 33% | 0.06% / 5% | ✗ NOT HALAL |
| MSCI | 1.3% / 33% | 97.0% / 33% | 0.0% / 33% | 0.06% / 5% | ✗ NOT HALAL |
| S&P | 1.6% / 33% | 117.4% / 33% | 0.0% / 33% | 0.06% / 5% | ✗ NOT HALAL |
| FTSE | 1.3% / 33% | 97.0% / 33% | 0.0% / 50% | 0.06% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -137.8% | |
| Operating Margin | -3387.9% | |
| Net Margin | -265.9% | |
| Return on Assets (ROA) | -399.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$41M |
| Free Cash Flow | -$43M |
| Total Debt | $4M |
| Current Ratio | 0.1 |
| Total Assets | $278M |
Price & Trading
| Last Close | $13.10 |
| 50-Day MA | $14.11 |
| 200-Day MA | $14.11 |
| Avg Volume | 1.6M |
|
52-Week Range
$11.95
| |
About Avidity Biosciences, Inc. (RNA)
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Avidity Biosciences, Inc. (RNA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Avidity Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Avidity Biosciences, Inc.'s debt ratio?
Avidity Biosciences, Inc.'s debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.3%.
What are Avidity Biosciences, Inc.'s key financial metrics?
Avidity Biosciences, Inc. has a market capitalization of $205M, and revenue of $19M. The company maintains a gross margin of -137.8% and a net margin of -265.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.